Neurontin Litigators > Neurontin Marketing

For Neurontin litigators, the case against the creators of Neurontin is well-documented and the evidence against the creators of the drug is abundant. Through years of government investigation and with the help of former employees of the company, users of Neurontin have been given the opportunity to receive compensation after being severely wronged as a result of the strategy for marketing Neurontin. The information below outlines the "big picture" regarding the marketing of the drug.

Neurontin was approved by the FDA as a treatment for epilepsy. The off-label use of Neurontin has been controversial as uncovered evidence shows strategic planning by Pfizer Inc., who acquired Parke-Davis the original producer of Neurontin, in order to allow the drug to become a “blockbuster hit."

A drug is considered a blockbuster when its total sales top $1 billion per year. Neurontin was able to accomplish this feat despite what is considered to be a small market with little upward sales mobility for epilepsy treatment.

The FDA sent warning letters to the creator of Neurontin marketing materials that violated agency rules. Still, Neurontin was able to grow into an over $1.3 billion per year blockbuster hit, with estimates up to 90% of Neurontin’s sales attributed to off-label sales. A former Parke-Davis employee turned whistle-blower claims Neurontin experienced boosted sales after the drug company gave doctors thousands of dollars to promote off-label uses of Neurontin at medical meetings.

According to the Public Citizen consumer advocacy group, the evidence gathered over the years against the creators of the drug “is the most complete and well-documented case of off-label promotion to ever come into public view.” This makes the task of recovering damages easy for Neurontin litigators.